What is the proposed acquisition price for QIAGEN?

Thermo Fisher Scientific Inc. is offering to acquire QIAGEN N.V. for €39 per share in cash.

Is this acquisition dependent on Thermo Fisher securing financing?

No, the tender offer is not subject to any financing condition, as Thermo Fisher has obtained committed debt financing from JPMorgan Chase Bank, N.A and Morgan Stanley Senior Funding, Inc.

What are the key conditions for the tender offer to close?

Key conditions include at least 75% of QIAGEN's shares being validly tendered and not withdrawn, the receipt of required antitrust clearances (including HSR and EU approval), the QIAGEN Boards not changing their recommendation, and the absence of any material adverse effect on QIAGEN.

What happens to QIAGEN's stock and reporting obligations after the acquisition?

It is expected that QIAGEN will no longer be a publicly traded company following the offer closing, its shares will be delisted from the NYSE and Frankfurt Stock Exchange, and its U.S. and German securities law reporting obligations will cease.

Are there any penalties if the deal falls apart?

Yes, if the Combination Agreement is terminated under certain circumstances (e.g., QIAGEN entering into a competing offer agreement), QIAGEN may be obligated to pay Thermo Fisher a termination fee of $367 million. Conversely, Thermo Fisher may be obligated to pay QIAGEN a reverse termination fee of $575 million if the deal fails due to the inability to obtain required antitrust clearances by the Long Stop Date.

TMO 8-K: Material Agreements

Summary

Thermo Fisher Scientific Inc. announced a significant strategic move on March 3, 2020, entering into a Business Combination Agreement to acquire QIAGEN N.V. through a public tender offer. The offer price is set at €39 per share in cash, valuing the acquisition at a substantial amount and representing a significant premium for QIAGEN shareholders. This acquisition is not subject to any financing condition, as Thermo Fisher has secured committed debt financing. The transaction is expected to be a transformative step for Thermo Fisher, expanding its presence in the life sciences and diagnostics markets. The deal is contingent upon customary closing conditions, including a minimum tender of 75% of QIAGEN's shares and the satisfaction of various antitrust and regulatory approvals. The process includes a tender offer period of at least ten weeks, with provisions for an extension. Post-acquisition, Thermo Fisher plans to integrate QIAGEN, potentially delisting it from public exchanges. The agreement also outlines termination clauses and associated fees, including a substantial termination fee payable by QIAGEN if it accepts a superior offer and a reverse termination fee payable by Thermo Fisher under specific circumstances, such as the failure to obtain regulatory approvals.

Key Highlights

1Thermo Fisher Scientific Inc. (TMO) is acquiring QIAGEN N.V. via a cash tender offer for €39 per share.
2The acquisition is structured as a public tender offer, not subject to financing conditions, with committed debt financing secured.
3The offer requires a minimum tender of 75% of QIAGEN's outstanding shares and is subject to regulatory and antitrust approvals.
4The tender offer period is set for at least ten weeks, with potential for extensions.
5Post-acquisition, QIAGEN is expected to be delisted from public exchanges.
6The agreement includes termination rights for both parties and associated termination fees, with a €367 million fee payable by QIAGEN under certain conditions and a $575 million reverse termination fee payable by Thermo Fisher if antitrust approvals are not obtained.
7The transaction is expected to be a material event for Thermo Fisher, significantly expanding its life sciences and diagnostics capabilities.

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Mar 9, 2020)

Summary

Key Highlights

Frequently Asked Questions